Medicines: new game, new rules
Pathways to better and affordable medicines

2016 was a year of political recognition that imbalances exist in the pharmaceutical system along with widespread concerns about the sustainability of healthcare systems in Europe. The price of both old and new medicines has been rising dramatically, leading to rationing of medicines for patients and other access to treatment challenges. These problems are the result of a dysfunctional R&D system that prioritises profits over public health imperatives and individual patients’ needs.

This session will respond to the calls by EU and national policy-makers for actionable policy recommendations. It will articulate a set of short, mid and long-term policy proposals in the area of incentives for drug development and the need for public health needs-driven regulatory reform in Europe, to guarantee genuine therapeutic advance for the benefit of all patients.

Welcome & introductory remarks

KITI KAJANA PHILLIPS
Program Officer, Access to Medicines & Innovation, Public Health Program, Open Society Foundations (OSF)

Panel I – Do we get the medicines we need and can afford?

SUE RIE MOON
Director of Research at the Global Health Centre, Graduate Institute of International and Development Studies, Geneva, and Adjunct Lecturer on Global Health at the Harvard T.H. Chan School of Public Health

COURTNEY DAVIS
Director of the Masters in Medicine, Health and Public Policy, Department of Global Health and Social Medicine, Kings College London

AJAY AGGARWAL
Consultant clinical oncologist, Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine

LIVIO GARATTINI
Director, Angelo & Angela Valenti - Centre of Health Economics (CESAV), Mario Negri Institute, Italy

Moderated by DEBORAH COHEN, Associate Editor, British Medical Journal (BMJ)

Panel II – The access to medicines problems in Europe: What can governments do?

MARCEL VAN RAAI J
Director Medicines & Medical Technology, Ministry of Health, Welfare and Sport, The Netherlands

CLEMENS MARTIN AUER
Director General, Ministry of Health & Women’s Affairs, Austria, and President, European Health Forum Gastein

MELANIE KEN NEDY
Patient Advocate, Just Treatment, UK

MARTIN MUNTE
President, Pharmig - Association of the Austrian Pharmaceutical Industry, and Chief Executive Officer, Amgen

YANNIS NATSIS
Policy Manager, Universal Access & Affordable Medicines, European Public Health Alliance (EPHA)

Moderated by MARTIN MCKEE, Professor, London School of Hygiene and Tropical Medicine